Sareum Holdings PLC Sareum to Present at AACR-NCI-EORTC Conference
November 29 2016 - 2:01AM
RNS Non-Regulatory
TIDMSAR
Sareum Holdings PLC
29 November 2016
(AIM: SAR) 29 November 2016
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Sareum to Present TYK2 Cancer Research Programme
at the 2016 AACR-NCI-EORTC International Conference
Sareum Holdings plc, the specialist cancer drug discovery and
development business, is pleased to announce that it will present
the latest results from its TYK2 cancer research programme at the
American Association for Cancer Research (AACR) National Cancer
Institute (NCI) European Organisation for Research and Treatment of
Cancer (EORTC) International Conference, to be held between 29
November and 2 December 2016 in Munich, Germany.
On Tuesday 29 November, Sareum's CSO, Dr John Reader, will
present a poster(*) that describes the discovery of the TKY2
anti-cancer programme lead compounds and their effectiveness in a
disease model of T-Cell Acute Lymphoblastic Leukaemia (T-ALL).
The Company announced, on 24 October, that a feasibility study
into the potential for its TYK2 inhibitors to treat T-ALL, part
funded by the Innovate UK BioMedical Catalyst, had concluded
successfully. The study culminated in a T-ALL disease model study
in which Sareum's compounds, dosed orally, were well tolerated,
presented good exposure to plasma and tumour tissue and showed a
dose-dependent effect on a biomarker of TYK2 inhibition and tumour
reduction of up to 80%.
* Session "Molecular Targeted Agents I"
"Characterisation of TYK2 Inhibitors as Potential T-cell Acute
Lymphoblastic Leukaemia Therapeutics." Abstract #48, Poster Board
#19
Sareum's CEO, Dr Tim Mitchell, commented: "Sareum's progress
with TYK2 inhibitors as anti-cancer agents adds significant value
to our success with these compounds in autoimmune disease models.
We are delighted to be presenting these results at this important
cancer conference, which we expect representatives from most of our
potential customer companies to attend. "
For further information:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser and
Co-Broker)
Chris Fielding / Nick Prowting 020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce / William Lynne 020 3764 2341/2342
The Communications Portfolio
(Sareum Media enquiries)
Ariane Comstive
Ariane.comstive@communications-portfolio.co.uk 07785 922 354
Notes for editors:
Sareum is a drug discovery and development company delivering
targeted small molecule therapeutics, focusing on cancer and
autoimmune disease, for licensing to pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum operates an outsourced research model, working with
international collaborators and a world-wide network of research
providers. Its most advanced programme (Chk1) commenced clinical
trials in May 2016 and was licensed to NASDAQ-listed ProNAi
Therapeutics in September 2016.
SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug
discovery technology platform that has so far produced the
Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease
research programmes, which are in the IND-enabling preclinical and
lead optimisation stages respectively. SKIL(R) can also generate
drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the symbol SAR. For further
information, please visit www.sareum.co.uk
T-Cell Acute Lymphoblastic Leukaemia (T-ALL) is a rare type of
leukaemia that is more common in older children and teenagers. It
affects a type of white blood cell called T-cells. It is aggressive
and progresses quickly. Around 200 people are diagnosed with T-ALL
in the UK every year. It usually occurs in late childhood or early
adolescence and is significantly more common in boys than
girls.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADVLFLQFFEFBV
(END) Dow Jones Newswires
November 29, 2016 02:01 ET (07:01 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From May 2024 to Jun 2024
Sareum (LSE:SAR)
Historical Stock Chart
From Jun 2023 to Jun 2024